Cargando…

Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c(+)CD8(+) T cells in renal cell carcinoma

To improve the potential treatment strategies of incurable renal cell carcinoma (RCC), which is highly resistant to chemotherapy and radiotherapy, the present study established a combination therapy with immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) to augment the antit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Seong-A, Park, Sang-Min, Joe, Yeonsoo, Chung, Hun Taeg, An, Won G., Kim, Byung-Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674882/ https://www.ncbi.nlm.nih.gov/pubmed/34976155 http://dx.doi.org/10.3892/ol.2021.13161

Ejemplares similares

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes
por: You, Gihoon, et al.
Publicado: (2021)

T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells
Publicado: (1994)

Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells
por: Li, Jing, et al.
Publicado: (2016)

Temporary, but Essential Requirement of CD8(+) T Cells Early in the Pathogenesis of Diabetes in BB Rats as Revealed by Thymectomy and CD8 Depletion
por: Groen, Herman, et al.
Publicado: (2003)

The Vbeta13 T Cell Receptor Monoclonal Antibody Reduces Hyaluronan and CD68+, CD3+, and CD8+ Cell Infiltrations to Delay Diabetes in Congenic BB DRLyp/Lyp Rats
por: Bogdani, Marika, et al.
Publicado: (2021)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8(+) T Cells
por: Stairiker, Christopher J., et al.
Publicado: (2021)

4‐1BB costimulation promotes bystander activation of human CD8 T cells
por: Reithofer, Manuel, et al.
Publicado: (2020)

Hypoxia and antitumor CD8(+) T cells: An incompatible alliance?
por: Vuillefroy de Silly, Romain, et al.
Publicado: (2016)

Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8(+)T cell antitumor function
por: Pellom, Samuel T., et al.
Publicado: (2016)

A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
por: Konstorum, Anna, et al.
Publicado: (2019)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma
por: Kim, Hyung‐Don, et al.
Publicado: (2019)

Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells
por: Humphreys, Ian R, et al.
Publicado: (2010)

4-1BB Signaling Breaks the Tolerance of Maternal CD8(+) T Cells That Are Reactive with Alloantigens
por: Kim, Kwang H., et al.
Publicado: (2012)

Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases
por: Chung, Hun Taeg, et al.
Publicado: (2014)

Regulation of CD8(+) T Cells and Antitumor Immunity by Notch Signaling
por: Tsukumo, Shin-ichi, et al.
Publicado: (2018)

Creatine uptake regulates CD8 T cell antitumor immunity
por: Di Biase, Stefano, et al.
Publicado: (2019)

CD38/ADP-ribose/TRPM2-mediated nuclear Ca(2+) signaling is essential for hepatic gluconeogenesis in fasting and diabetes
por: Rah, So-Young, et al.
Publicado: (2023)

The involvement of 4‐1BB/4‐1BBL signaling in glial cell‐mediated hypothalamic inflammation in obesity
por: Kim, Jiye, et al.
Publicado: (2018)

Antitumor Immunity Produced by the Liver Kupffer Cells, NK Cells, NKT Cells, and CD8(+) CD122(+) T Cells
por: Seki, Shuhji, et al.
Publicado: (2011)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

NKT cell-targeted vaccination plus anti-4–1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma
por: Kobayashi, Takumi, et al.
Publicado: (2015)

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
por: Otano, Itziar, et al.
Publicado: (2021)

Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8(+) T Cells
por: Qin, Yingyu, et al.
Publicado: (2018)

Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction
por: Nabe, Shogo, et al.
Publicado: (2018)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Host type I IFN signals are required for antitumor CD8(+) T cell responses through CD8α(+) dendritic cells
por: Fuertes, Mercedes B., et al.
Publicado: (2011)

Role of 4-1BB Receptor in the Control Played by CD8(+) T Cells on IFN-γ Production by Mycobacterium tuberculosis Antigen-Specific CD4(+) T Cells
por: Palma, Carla, et al.
Publicado: (2010)

CD8α(2) CD11b(+) Dendritic Cells Present Exogenous Virus-like Particles to CD8(+) T Cells and Subsequently Express CD8α and CD205 Molecules
por: Morón, Gabriel, et al.
Publicado: (2002)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020)

Regulation of CD4(+)CD8(−)CD25(+) and CD4(+)CD8(+)CD25(+) T cells by gut microbiota in chicken
por: Lee, In Kyu, et al.
Publicado: (2018)

The Cell Cycle Time of CD8(+) T Cells Responding In Vivo Is Controlled by the Type of Antigenic Stimulus
por: Yoon, Heesik, et al.
Publicado: (2010)

Antiviral CD8(+) T cell effector activities in situ are regulated by target cell type
por: Hufford, Matthew M., et al.
Publicado: (2011)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response
por: Reiser, John, et al.
Publicado: (2016)

CD8(+) T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma
por: Xu, Chun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8cjn9kedcu989v41piafacao41